Endocrine Abstracts

Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with dysregulated glucocorticoid metabolism. Advanced stages of NAFLD are associated with adverse outcome and current strategies to stage disease severity are still reliant upon liver biopsy. We have previously described changes to enzymatic pathways that regulate cortisol bioavailability; 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) regenerates cortisol from inactive cortisone, and A-ring re...

Introduction: The development of accurate non-invasive markers to diagnose and stage non-alcoholic fatty liver disease (NAFLD) is of high importance to reduce the need for an invasive liver biopsy. These markers help to stratify patients at highest risk of hepatic and cardio-metabolic complications and allow tracking of disease progression and treatment response. We have previously described alterations in glucocorticoid metabolism that are differentially regulated across the ...